BRENNEN

Industries / Health / Pharmaceuticals

Contract drug manufacturing

Contract drug manufacturing is the industry of companies, called CDMOs (contract development and manufacturing organizations), that work out how to make a drug company's medicine and then make it, in their own plants, under contract.

1933

Robert Pauli Scherer, a chemical engineer in Detroit, founded the Gelatin Products Company to make soft gelatin capsules on a rotary die machine he had invented, and it soon took work from a growing list of drug makers; the analyst Jim Miller names R.P. Scherer among the few dedicated contract makers of finished medicines before 1996.

detroithistorical.orgfundinguniverse.compharmtech.com

36

Milestones achieved across 6 domains.

10

To watch for: announced, not yet confirmed outside.

12

Open deliverables. Nobody has shipped them.

In one minute

Where it started

Before 1996, by Jim Miller's account in Pharmaceutical Technology, large drug companies made products for one another on an informal basis, fine-chemical firms made the building blocks, and a few specialists filled narrow niches: R.P. Scherer made soft capsules, Ben Venue Laboratories freeze-dried injectable drugs and Vetter filled syringes. There was no contract sector for medicines grown in cells, so Amgen and Genentech built their own plants. From 1996 Custom Pharmaceuticals became Patheon and bought plants that drug companies were shedding, Lonza bought Celltech's contract biologics business, and Cardinal Health bought R.P. Scherer, the first piece of what became Catalent.

Where it stands

Contract makers now run plants as large as those of the companies they serve. Lonza, which now does only contract work, reported 2025 sales of CHF 6.5 billion, and in 2024 it bought a whole Genentech plant from Roche. Samsung Biologics, founded in 2011, says its plants hold 784,000 litres of cell-culture tanks. Drug companies also buy plants back: Novo Holdings bought Catalent in December 2024 and passed three of its filling plants to Novo Nordisk. Governments treat the industry as a question of supply. India pays makers to produce ingredients at home, the US BIOSECURE Act of December 2025 limits federal money for "biotechnology companies of concern", and the FDA now inspects more foreign plants without warning.

What is open

Most of what a contract maker knows sits in private files: the process it was handed, the quality agreement it signed, its schedule and its run data. The open jobs below build public versions from records that are already published, such as regulators' product files, warning letters, company filings and worked case studies, and use them to test current AI models and low-cost robots. None of them needs a drug, a plant or a licence.

Domains

AchievedWatch forOpen

Advances to build with

1 research note

Open in contract drug manufacturing

3 of 12 open deliverables

Open · Process development

Route planners against plant routes

A test set of approved, non-controlled small-molecule medicines for which both the first published route and the route used for commercial manufacture are public, for example in Organic Process Research & Development papers. Route-planning software proposes a route for each target, and each plan is scored on number of steps, whether its starting materials can be bought, estimated PMI and how close it comes to the commercial route.

Built with what exists

AiZynthFinder (AstraZeneca, MIT licence) and ASKCOS, both open source; commercial planners such as Elsevier's Reaxys synthesis planning, which Lonza uses in its route-scouting service; the RetroCast scoring approach; the ACS GCI PMI calculators. An open-weight model such as Mistral Large 4 can be added as a further entrant; the note "A trillion open parameters" covers its release and licence.

Credit · unclaimed

Open · Active ingredients

Ingredient makers by medicine

For each of the 370 WHO essential medicines on the US market that the FDA examined in 2019, a public list of the companies holding an active US drug master file (DMF, the file an API maker lodges with the FDA so its clients can refer to it) or a European certificate of suitability (CEP) for its API, with each holder's country, refreshed every quarter. It shows who can supply, not who does.

Built with what exists

the FDA's quarterly DMF list (third quarter 2026, a 51.5 MB spreadsheet); the European Directorate for the Quality of Medicines' certificates catalogue (holder name, CEP type and number); a language model to match holder names to countries, with a person checking each match.

Credit · unclaimed

Open · Biologics

Who makes each antibody

A public table of every antibody medicine authorised in the European Union. Each row names a plant listed as a maker of the medicine's active substance, says whether that plant belongs to the drug's owner or to a contract maker, and quotes the source line.

Built with what exists

The EMA's product-information PDFs; pdftotext; Python; a language model such as Claude to pull plant names and addresses, with a person checking each one. The note "Seven more flagged" covers Claude reviewing drug-making records.

Credit · unclaimed

Where it sits